| Tacrolimus | hsa00052 | Galactose metabolism | 1.12E-04 | 2 | P06280, O43451 | GLA, MGAM | More | |
| Tacrolimus | hsa00280 | Valine, leucine and isoleucine degradation | 3.41E-03 | 4 | P55809, Q9HCC0, Q02252, P11310 | OXCT1, MCCC2, ALDH6A1, ACADM | More | |
| Tacrolimus | hsa00500 | Starch and sucrose metabolism | 3.16E-04 | 2 | O43451, P06737 | MGAM, PYGL | More | |
| Tacrolimus | hsa00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 3.43E-02 | 1 | Q9NY97 | B3GNT2 | More | |
| Tacrolimus | hsa00730 | Thiamine metabolism | 2.53E-05 | 2 | P05186, P24666 | ALPL, ACP1 | More | |
| Tacrolimus | hsa00770 | Pantothenate and CoA biosynthesis | 5.59E-03 | 2 | O95498, O95497 | VNN2, VNN1 | More | |
| Tacrolimus | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 3.20E-02 | 2 | P78417, P11766 | GSTO1, ADH5 | More | |
| Tacrolimus | hsa00982 | Drug metabolism - cytochrome P450 | 3.20E-02 | 2 | P78417, P11766 | GSTO1, ADH5 | More | |
| Tacrolimus | hsa00983 | Drug metabolism - other enzymes | 2.44E-02 | 2 | P32320, P05164 | CDA, MPO | More | |
| Tacrolimus | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 4.26E-03 | 3 | P17252, P04049, Q9NRA1 | PRKCA, RAF1, PDGFC | More | |
| Tacrolimus | hsa01522 | Endocrine resistance | 2.16E-02 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa03013 | RNA transport | 4.13E-02 | 6 | Q09161, P35658, P47813, Q14152, O75822, P51114 | NCBP1, NUP214, EIF1AX, EIF3A, EIF3J, FXR1 | More | |
| Tacrolimus | hsa03060 | Protein export | 4.22E-02 | 2 | P37108, Q15005 | SRP14, SPCS2 | More | |
| Tacrolimus | hsa04010 | MAPK signaling pathway | 4.15E-02 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa04012 | ErbB signaling pathway | 1.82E-02 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa04014 | Ras signaling pathway | 1.04E-04 | 6 | P04049, Q9NRA1, P49767, P17252, Q14644, P62873 | RAF1, PDGFC, VEGFC, PRKCA, RASA3, GNB1 | More | |
| Tacrolimus | hsa04015 | Rap1 signaling pathway | 5.45E-05 | 6 | P04049, Q9NRA1, P49767, P25116, P08514, P17252 | RAF1, PDGFC, VEGFC, F2R, ITGA2B, PRKCA | More | |
| Tacrolimus | hsa04020 | Calcium signaling pathway | 2.39E-03 | 4 | P17252, P25116, Q9NRA1, P49767 | PRKCA, F2R, PDGFC, VEGFC | More | |
| Tacrolimus | hsa04022 | cGMP-PKG signaling pathway | 3.15E-02 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa04024 | cAMP signaling pathway | 2.49E-02 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa04060 | Cytokine-cytokine receptor interaction | 3.62E-02 | 4 | P27930, P14778, P25024, P25025 | IL1R2, IL1R1, CXCR1, CXCR2 | More | |
| Tacrolimus | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 2.60E-02 | 3 | Q8NHW4, P61073, Q13651 | CCL4L2, CXCR4, IL10RA | More | |
| Tacrolimus | hsa04062 | Chemokine signaling pathway | 3.98E-02 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa04064 | NF-kappa B signaling pathway | 4.09E-03 | 5 | P01584, P67870, P63279, Q8NHW4, Q9NQC7 | IL1B, CSNK2B, UBE2I, CCL4L2, CYLD | More | |
| Tacrolimus | hsa04068 | FoxO signaling pathway | 1.99E-02 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa04071 | Sphingolipid signaling pathway | 2.50E-03 | 8 | P04049, Q9H228, P01375, Q13362, Q9BX95, Q16539, P10415, Q9UQC2 | RAF1, EDG8, TNF, PPP2R5C, SGPP1, MAPK14, BCL2, GAB2 | More | |
| Tacrolimus | hsa04072 | Phospholipase D signaling pathway | 1.50E-05 | 8 | P04049, Q9UQC2, P25116, P25024, P25025, P17252, P23743, Q9NRA1 | RAF1, GAB2, F2R, CXCR1, CXCR2, PRKCA, DGKA, PDGFC | More | |
| Tacrolimus | hsa04114 | Oocyte meiosis | 1.33E-02 | 4 | P51812, Q02750, P16298, Q17RY0 | RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | |
| Tacrolimus | hsa04140 | Autophagy - animal | 2.82E-02 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa04150 | mTOR signaling pathway | 7.74E-03 | 4 | P04049, Q02750, Q9NQL2, P51812 | RAF1, MAP2K1, RRAGD, RPS6KA3 | More | |
| Tacrolimus | hsa04151 | PI3K-Akt signaling pathway | 1.71E-03 | 6 | P25116, Q9NRA1, P49767, P62873, P08514, P17252 | F2R, PDGFC, VEGFC, GNB1, ITGA2B, PRKCA | More | |
| Tacrolimus | hsa04210 | Apoptosis | 3.64E-03 | 5 | O76075, P01375, Q9NR28, Q16548, P04049 | DFFB, TNF, DIABLO, BCL2A1, RAF1 | More | |
| Tacrolimus | hsa04215 | Apoptosis - multiple species | 1.56E-02 | 2 | Q13489, P10415 | BIRC3, BCL2 | More | |
| Tacrolimus | hsa04218 | Cellular senescence | 2.49E-02 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa04260 | Cardiac muscle contraction | 4.49E-02 | 3 | P67936, P13073, P12074 | TPM4, COX4I1, COX6A1 | More | |
| Tacrolimus | hsa04270 | Vascular smooth muscle contraction | 2.32E-02 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa04340 | Hedgehog signaling pathway | 4.15E-03 | 4 | P49841, P22694, Q13635, P10415 | GSK3B, PRKACB, PTCH1, BCL2 | More | |
| Tacrolimus | hsa04360 | Axon guidance | 2.49E-02 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa04370 | VEGF signaling pathway | 1.79E-04 | 4 | P16298, Q05397, Q02750, P04049 | PPP3CB, PTK2, MAP2K1, RAF1 | More | |
| Tacrolimus | hsa04371 | Apelin signaling pathway | 1.54E-02 | 5 | P63218, P50151, P04049, Q14344, Q13485 | GNG5, GNG10, RAF1, GNA13, SMAD4 | More | |
| Tacrolimus | hsa04390 | Hippo signaling pathway | 2.08E-02 | 3 | P84022, Q13485, Q13489 | SMAD3, SMAD4, BIRC3 | More | |
| Tacrolimus | hsa04510 | Focal adhesion | 1.25E-03 | 5 | P08514, P17252, P04049, Q9NRA1, P49767 | ITGA2B, PRKCA, RAF1, PDGFC, VEGFC | More | |
| Tacrolimus | hsa04512 | ECM-receptor interaction | 3.19E-02 | 2 | P07359, P08514 | GP1BA, ITGA2B | More | |
| Tacrolimus | hsa04540 | Gap junction | 1.78E-04 | 4 | P17252, P68371, P04049, Q9NRA1 | PRKCA, TUBB2C, RAF1, PDGFC | More | |
| Tacrolimus | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 1.99E-02 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa04611 | Platelet activation | 7.90E-03 | 3 | P25116, P08514, P07359 | F2R, ITGA2B, GP1BA | More | |
| Tacrolimus | hsa04612 | Antigen processing and presentation | 2.40E-02 | 8 | P13765, P48382, P26715, P26717, Q13241, O43908, P01732, P01375 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRD1, KLRC4, CD8A, TNF | More | |
| Tacrolimus | hsa04613 | Neutrophil extracellular trap formation | 6.10E-04 | 18 | P17252, P04049, O60603, P05164, P08246, Q9UM07, Q6FI13, O60814, Q15080, P20160, P08311, O75015, P21730, P08514, P21462, P07359, O43315, Q16539 | PRKCA, RAF1, TLR2, MPO, ELA2, PADI4, H2AC18; H2AC19, H2BC12, NCF4, AZU1, CTSG, FCGR3B, C5AR1, ITGA2B, FPR1, GP1BA, AQP9, MAPK14 | More | |
| Tacrolimus | hsa04621 | NOD-like receptor signaling pathway | 2.62E-02 | 11 | Q16539, Q14643, P10599, Q9H1Y0, P43490, O00463, P10415, Q05823, P01375, P09341, P12838 | MAPK14, ITPR1, TXN, ATG5, PBEF1, TRAF5, BCL2, RNASEL, TNF, CXCL1, DEFA4 | More | |
| Tacrolimus | hsa04623 | Cytosolic DNA-sensing pathway | 1.54E-02 | 2 | P01584, Q8NHW4 | IL1B, CCL4L2 | More | |
| Tacrolimus | hsa04625 | C-type lectin receptor signaling pathway | 1.49E-02 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa04630 | JAK-STAT signaling pathway | 1.49E-02 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa04640 | Hematopoietic cell lineage | 2.96E-02 | 3 | P07359, P08514, P04141 | GP1BA, ITGA2B, CSF2 | More | |
| Tacrolimus | hsa04650 | Natural killer cell mediated cytotoxicity | 4.37E-03 | 4 | P16298, P50591, Q02750, P04049 | PPP3CB, TNFSF10, MAP2K1, RAF1 | More | |
| Tacrolimus | hsa04657 | IL-17 signaling pathway | 5.82E-03 | 7 | O00463, Q16539, P49841, P09341, P14780, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, MMP9, LCN2, TNF | More | |
| Tacrolimus | hsa04658 | Th1 and Th2 cell differentiation | 1.12E-02 | 8 | Q04759, P20963, P09693, Q16539, Q14765, P23771, Q9UL17, P13765 | PRKCQ, CD247, CD3G, MAPK14, STAT4, GATA3, TBX21, HLA-DOB | More | |
| Tacrolimus | hsa04659 | Th17 cell differentiation | 3.17E-02 | 3 | P25963, P84022, Q13485 | NFKBIA, SMAD3, SMAD4 | More | |
| Tacrolimus | hsa04660 | T cell receptor signaling pathway | 2.18E-04 | 12 | P01375, Q9UDY8, Q04759, O95267, Q08881, P20963, P09693, P01732, Q13191, P04049, Q16539, P49841 | TNF, MALT1, PRKCQ, RASGRP1, ITK, CD247, CD3G, CD8A, CBLB, RAF1, MAPK14, GSK3B | More | |
| Tacrolimus | hsa04662 | B cell receptor signaling pathway | 9.95E-03 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa04664 | Fc epsilon RI signaling pathway | 2.19E-03 | 3 | P04141, P17252, P04049 | CSF2, PRKCA, RAF1 | More | |
| Tacrolimus | hsa04666 | Fc gamma R-mediated phagocytosis | 2.32E-02 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa04713 | Circadian entrainment | 4.51E-02 | 2 | P17252, P62873 | PRKCA, GNB1 | More | |
| Tacrolimus | hsa04720 | Long-term potentiation | 2.17E-03 | 4 | P16298, P51812, Q02750, P04049 | PPP3CB, RPS6KA3, MAP2K1, RAF1 | More | |
| Tacrolimus | hsa04722 | Neurotrophin signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa04723 | Retrograde endocannabinoid signaling | 3.83E-02 | 2 | P17252, P62873 | PRKCA, GNB1 | More | |
| Tacrolimus | hsa04724 | Glutamatergic synapse | 3.09E-03 | 3 | P17252, P62873, Q9NSB8 | PRKCA, GNB1, HOMER2 | More | |
| Tacrolimus | hsa04725 | Cholinergic synapse | 3.83E-02 | 2 | P17252, P62873 | PRKCA, GNB1 | More | |
| Tacrolimus | hsa04726 | Serotonergic synapse | 4.07E-04 | 4 | P17252, P62873, P18054, P04049 | PRKCA, GNB1, ALOX12, RAF1 | More | |
| Tacrolimus | hsa04727 | GABAergic synapse | 2.06E-02 | 2 | P62873, P17252 | GNB1, PRKCA | More | |
| Tacrolimus | hsa04730 | Long-term depression | 1.08E-02 | 3 | Q14344, P04049, P07948 | GNA13, RAF1, LYN | More | |
| Tacrolimus | hsa04750 | Inflammatory mediator regulation of TRP channels | 4.51E-02 | 2 | P18054, P17252 | ALOX12, PRKCA | More | |
| Tacrolimus | hsa04810 | Regulation of actin cytoskeleton | 5.85E-03 | 4 | P04049, P08514, Q9NRA1, P25116 | RAF1, ITGA2B, PDGFC, F2R | More | |
| Tacrolimus | hsa04910 | Insulin signaling pathway | 2.51E-03 | 4 | P22694, P06737, P04049, P49841 | PRKACB, PYGL, RAF1, GSK3B | More | |
| Tacrolimus | hsa04912 | GnRH signaling pathway | 1.82E-02 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa04914 | Progesterone-mediated oocyte maturation | 5.89E-03 | 4 | Q17RY0, P51812, Q02750, P04049 | CPEB4, RPS6KA3, MAP2K1, RAF1 | More | |
| Tacrolimus | hsa04915 | Estrogen signaling pathway | 2.99E-02 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa04916 | Melanogenesis | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa04917 | Prolactin signaling pathway | 6.63E-03 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa04918 | Thyroid hormone synthesis | 1.14E-02 | 2 | P17252, P27824 | PRKCA, CANX | More | |
| Tacrolimus | hsa04919 | Thyroid hormone signaling pathway | 6.83E-04 | 5 | P49841, P04049, P22694, O60244, Q9NVC6 | GSK3B, RAF1, PRKACB, MED14, MED17 | More | |
| Tacrolimus | hsa04921 | Oxytocin signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa04926 | Relaxin signaling pathway | 1.58E-03 | 4 | P62873, P49767, P04049, P17252 | GNB1, VEGFC, RAF1, PRKCA | More | |
| Tacrolimus | hsa04928 | Parathyroid hormone synthesis, secretion and action | 1.99E-02 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa04929 | GnRH secretion | 4.98E-03 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | |
| Tacrolimus | hsa04932 | Non-alcoholic fatty liver disease | 1.24E-02 | 6 | O43521, O75460, P01584, P13073, P12074, O15239 | BCL2L11, ERN1, IL1B, COX4I1, COX6A1, NDUFA1 | More | |
| Tacrolimus | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.25E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | |
| Tacrolimus | hsa04935 | Growth hormone synthesis, secretion and action | 2.16E-02 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa04975 | Fat digestion and absorption | 3.43E-02 | 1 | O14494 | PLPP1 | More | |
| Tacrolimus | hsa04976 | Bile secretion | 2.44E-02 | 2 | P22694, P08183 | PRKACB, ABCB1 | More | |
| Tacrolimus | hsa05010 | Alzheimer disease | 2.21E-02 | 10 | O15239, P13073, P12074, Q00535, O75460, P0DP23, P01584, O95197, P67870, P28070 | NDUFA1, COX4I1, COX6A1, CDK5, ERN1, CALM1, IL1B, RTN3, CSNK2B, PSMB4 | More | |
| Tacrolimus | hsa05032 | Morphine addiction | 1.20E-03 | 6 | P62873, P63218, P50151, Q07343, P17252, P43250 | GNB1, GNG5, GNG10, PDE4B, PRKCA, GRK6 | More | |
| Tacrolimus | hsa05034 | Alcoholism | 2.49E-02 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 3.73E-02 | 2 | P25024, P25025 | CXCR1, CXCR2 | More | |
| Tacrolimus | hsa05130 | Pathogenic Escherichia coli infection | 3.65E-02 | 3 | Q14247, P68371, P25116 | CTTN, TUBB2C, F2R | More | |
| Tacrolimus | hsa05132 | Salmonella infection | 6.67E-03 | 5 | P25963, P04049, Q13489, P10415, Q9BQS8 | NFKBIA, RAF1, BIRC3, BCL2, FYCO1 | More | |
| Tacrolimus | hsa05140 | Leishmaniasis | 1.87E-02 | 7 | P13612, O75015, P13765, O60603, P01375, Q16539, Q15080 | ITGA4, FCGR3B, HLA-DOB, TLR2, TNF, MAPK14, NCF4 | More | |
| Tacrolimus | hsa05145 | Toxoplasmosis | 2.78E-02 | 3 | P25963, P10415, Q13489 | NFKBIA, BCL2, BIRC3 | More | |
| Tacrolimus | hsa05146 | Amoebiasis | 3.91E-02 | 7 | P09341, P27930, P01375, O60603, P05089, P22694, P08311 | CXCL1, IL1R2, TNF, TLR2, ARG1, PRKACB, CTSG | More | |
| Tacrolimus | hsa05150 | Staphylococcus aureus infection | 2.44E-02 | 4 | P21462, Q14532, P59665, P59666 | FPR1, KRT32, DEFA1; DEFA1B, DEFA3 | More | |
| Tacrolimus | hsa05152 | Tuberculosis | 3.98E-02 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa05160 | Hepatitis C | 1.99E-02 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa05161 | Hepatitis B | 6.38E-04 | 5 | P04049, P25963, Q13485, P10415, P84022 | RAF1, NFKBIA, SMAD4, BCL2, SMAD3 | More | |
| Tacrolimus | hsa05163 | Human cytomegalovirus infection | 1.53E-02 | 8 | P04049, P0DP23, Q8NHW4, Q08828, P23458, P01584, P61073, Q13651 | RAF1, CALM1, CCL4L2, ADCY1, JAK1, IL1B, CXCR4, IL10RA | More | |
| Tacrolimus | hsa05164 | Influenza A | 3.65E-02 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 4.57E-03 | 5 | P62879, P16298, P04049, Q02750, P0CG47 | GNB2, PPP3CB, RAF1, MAP2K1, UBB | More | |
| Tacrolimus | hsa05170 | Human immunodeficiency virus 1 infection | 1.31E-03 | 6 | P04049, Q02750, P62879, P16298, Q05397, P20333 | RAF1, MAP2K1, GNB2, PPP3CB, PTK2, TNFRSF1B | More | |
| Tacrolimus | hsa05200 | Pathways in cancer | 1.37E-02 | 6 | P08514, P17252, P49767, P25116, P62873, P78417 | ITGA2B, PRKCA, VEGFC, F2R, GNB1, GSTO1 | More | |
| Tacrolimus | hsa05202 | Transcriptional misregulation in cancer | 3.00E-02 | 13 | P14780, P27930, Q15744, Q16548, Q13077, P35226, P05164, P12838, P08246, Q9C0K0, P41182, P12980, P24522 | MMP9, IL1R2, CEBPE, BCL2A1, TRAF1, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, LYL1, GADD45A | More | |
| Tacrolimus | hsa05205 | Proteoglycans in cancer | 8.61E-03 | 4 | Q12955, P04049, Q14247, P17252 | ANK3, RAF1, CTTN, PRKCA | More | |
| Tacrolimus | hsa05206 | MicroRNAs in cancer | 3.15E-02 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa05210 | Colorectal cancer | 1.68E-03 | 4 | P84022, Q13485, P04049, P10415 | SMAD3, SMAD4, RAF1, BCL2 | More | |
| Tacrolimus | hsa05211 | Renal cell carcinoma | 1.16E-02 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa05212 | Pancreatic cancer | 3.44E-03 | 3 | P04049, P84022, Q13485 | RAF1, SMAD3, SMAD4 | More | |
| Tacrolimus | hsa05213 | Endometrial cancer | 4.26E-03 | 3 | O15169, Q02750, P04049 | AXIN1, MAP2K1, RAF1 | More | |
| Tacrolimus | hsa05214 | Glioma | 9.95E-03 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa05215 | Prostate cancer | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa05218 | Melanoma | 6.63E-03 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa05219 | Bladder cancer | 4.98E-03 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa05220 | Chronic myeloid leukemia | 6.24E-04 | 4 | Q13485, P25963, P84022, P04049 | SMAD4, NFKBIA, SMAD3, RAF1 | More | |
| Tacrolimus | hsa05221 | Acute myeloid leukemia | 8.29E-03 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa05222 | Small cell lung cancer | 1.50E-02 | 3 | Q13489, P10415, P25963 | BIRC3, BCL2, NFKBIA | More | |
| Tacrolimus | hsa05223 | Non-small cell lung cancer | 6.63E-03 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa05224 | Breast cancer | 1.49E-02 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa05225 | Hepatocellular carcinoma | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa05226 | Gastric cancer | 2.93E-04 | 6 | P04049, Q02750, O15169, P84022, Q13485, P10415 | RAF1, MAP2K1, AXIN1, SMAD3, SMAD4, BCL2 | More | |
| Tacrolimus | hsa05230 | Central carbon metabolism in cancer | 9.95E-03 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa05231 | Choline metabolism in cancer | 1.78E-04 | 4 | P04049, Q9NRA1, P23743, P17252 | RAF1, PDGFC, DGKA, PRKCA | More | |
| Tacrolimus | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.66E-02 | 1 | P04049 | RAF1 | More | |
| Tacrolimus | hsa05310 | Asthma | 2.81E-02 | 3 | P13765, P12724, P01375 | HLA-DOB, RNASE3, TNF | More | |
| Tacrolimus | hsa05321 | Inflammatory bowel disease | 3.16E-03 | 6 | O60603, P01375, P13765, Q14765, Q9UL17, P23771 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3 | More | |
| Tacrolimus | hsa05332 | Graft-versus-host disease | 3.46E-02 | 4 | P13765, P01375, P26715, Q13241 | HLA-DOB, TNF, KLRC1, KLRD1 | More | |
